Form 8-K - Current report:
SEC Accession No. 0001493152-24-047143
Filing Date
2024-11-21
Accepted
2024-11-21 16:10:23
Documents
17
Period of Report
2024-11-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 53941
2 ex3-1.htm EX-3.1 178426
3 ex3-2.htm EX-3.2 146453
4 ex3-3.htm EX-3.3 118606
5 ex3-4.htm EX-3.4 65072
  Complete submission text file 0001493152-24-047143.txt   855577

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE qlgn-20241118.xsd EX-101.SCH 3009
7 XBRL LABEL FILE qlgn-20241118_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE qlgn-20241118_pre.xml EX-101.PRE 24161
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3691
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 241484462
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)